What are the benefits of vitamin K2? Evidence, claims & uses
Short answer
Vitamin K2 is best supported for improving vitamin K status markers in blood, especially osteocalcin and matrix Gla protein. The available trials do not prove disease prevention or treatment, and the strongest evidence is for biomarker shifts rather than hard clinical outcomes.
Quick facts
- MK-7 improved osteocalcin carboxylation in 12-week adult trials.
- Higher MK-7 doses reduced dp-ucMGP by about 31% and 46%.
- Natto is the richest verified food source, with about 850 µg MK-7 per 3 oz serving.
- Most common animal foods listed provide only single-digit micrograms per serving.
- MK-7 has a longer half-life, and both MK-4 and MK-7 are well absorbed.
- Vitamin K products are often combined with vitamin D, calcium or magnesium.

What are the proven benefits of vitamin K2?
In adults, the clearest benefit seen in the retrieved trials is better vitamin K status on blood markers linked to bone and vascular proteins, not proof of disease prevention. In a double-blind trial of 120 Japanese adults aged 20-69, 100 µg/day of MK-7 for 12 weeks increased the carboxylated-to-undercarboxylated osteocalcin ratio. In adults aged 40-65, 180 µg/day and 360 µg/day of MK-7 for 12 weeks reduced dp-ucMGP by about 31% and 46% and improved the osteocalcin ratio by 60% and 74%.
What that looks like in practice
Those numbers matter because they show that vitamin K2 can change the biochemical markers people use to track vitamin K-dependent proteins.
| Study | Population | MK-7 intake | What changed |
|---|---|---|---|
| 12 weeks | 120 Japanese adults, 20-69 years | 100 µg/day | Osteocalcin carboxylation marker improved (PubMed) |
| 12 weeks | Adults, 40-65 years | 180 µg/day and 360 µg/day | dp-ucMGP fell by about 31% and 46%; osteocalcin ratio improved by 60% and 74% (PubMed) |
Where the hard-outcome evidence stops
These studies do not show vitamin K2 as a treatment for heart disease, dementia, cancer, or performance. Even in hemodialysis patients, 360 µg of MK-7 three times per week for 18 months did not produce a statistically significant difference in coronary artery calcium progression. So the strongest evidence is for biomarker shifts, while clinical outcomes remain unproven or mixed.
Vitamin K2 is best supported as a nutrient that improves vitamin K status markers, not as a proven disease therapy.